Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma
Phase 2
Completed
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- CytoVac A/S
- Target Recruit Count
- 62
- Registration Number
- NCT02799238
- Locations
- 🇸🇪
Sahlgrenska University Hospital, Göteborg, Sweden
🇸🇪Ryhov hospital, Jönköping, Sweden
🇸🇪Skånes university hospital, Lund, Sweden
Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan
Phase 2
Terminated
- Conditions
- Glioblastoma Multiforme
- Interventions
- Drug: Bevacizumab/IrinotecanBiological: ALECSAT
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- CytoVac A/S
- Target Recruit Count
- 25
- Registration Number
- NCT02060955
- Locations
- 🇩🇰
Aalborg Universityhospital, Department of Oncology, Aalborg, Hobrovej 18-22, Denmark
🇩🇰Aarhus University Hospital, Department of Oncology, Aarhus, Nørrebrogade 44, Denmark
🇩🇰Odense University Hospital, Department of Oncology, Odense, Sdr. Boulevard 29, Denmark
A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients
Phase 1
Completed
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- CytoVac A/S
- Target Recruit Count
- 10
- Registration Number
- NCT01984658
- Locations
- 🇩🇰
Kirurgisk afdeling K, Bispebjerg Hospital, Copenhagen, Denmark
A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients
Phase 1
Completed
- Conditions
- Glioblastoma Multiforme
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- CytoVac A/S
- Target Recruit Count
- 23
- Registration Number
- NCT01588769
- Locations
- 🇩🇰
Department of Neurosurgery, Rigshospitalet, Copenhagen, Denmark
Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy
Phase 1
Completed
- Conditions
- Hormone-refractory Prostate Cancer
- First Posted Date
- 2011-08-24
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- CytoVac A/S
- Target Recruit Count
- 21
- Registration Number
- NCT01422850
- Locations
- 🇩🇰
Department of Urology, Frederikssund, Denmark
Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy
Phase 1
Completed
- Conditions
- Hormone-refractory Prostate Cancer
- First Posted Date
- 2009-05-01
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- CytoVac A/S
- Target Recruit Count
- 13
- Registration Number
- NCT00891345
- Locations
- 🇩🇰
Urological Clinic, Frederikssunds Hospital, Frederikssund, Denmark